… ProQR to Present its Ophthalmology Pipeline at ARVO, … in our ophthalmology pipeline at ARVO”, said Noreen R. Henig, Chief Medical Officer at ProQR. “These programs have many common elements with QR-110 …
… ProQR annonce des premiers résultats positifs pour l'essai de … CAMBRIDGE, Massachussets, 11 oct. 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq :PRQR), une entreprise dédiée … héréditaires dans son ensemble », a déclaré Stephen R. Russell, M.D., professeur Schrage d'ophtalmologie et des …
LEIDEN, Netherlands & CAMBRIDGE, Mass., April 23, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA therapies for
QR-421a showed early and encouraging evidence of activity, with 25% of patients showing a benefit across multiple concordant outcome measures and was well tolerated with no serious adverse eventsQR-421a is the second ophthalmology program where clinical activity was predicted by tra